Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

TARRYTOWN, N.Y. and PARIS , March 15, 2019 /PRNewswire/ —  Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack Praluent is the only EU-approved PCSK9 inhibitor with cardiovascular outcomes data that showed an

Original Source